Thermo Fisher Scientific Inc. (NYSE:TMO) Position Reduced by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 67.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,943 shares of the medical research company’s stock after selling 44,730 shares during the period. Los Angeles Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $11,647,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of TMO. Means Investment CO. Inc. lifted its stake in Thermo Fisher Scientific by 7.5% during the third quarter. Means Investment CO. Inc. now owns 858 shares of the medical research company’s stock valued at $435,000 after buying an additional 60 shares in the last quarter. KMG Fiduciary Partners LLC boosted its position in shares of Thermo Fisher Scientific by 6.7% in the third quarter. KMG Fiduciary Partners LLC now owns 3,304 shares of the medical research company’s stock worth $1,672,000 after buying an additional 207 shares during the period. Penobscot Wealth Management acquired a new position in Thermo Fisher Scientific during the third quarter valued at $204,000. Concord Wealth Partners boosted its holdings in shares of Thermo Fisher Scientific by 10.0% during the third quarter. Concord Wealth Partners now owns 884 shares of the medical research company’s stock worth $447,000 after purchasing an additional 80 shares during the period. Finally, Everhart Financial Group Inc. lifted its position in Thermo Fisher Scientific by 5.4% in the 3rd quarter. Everhart Financial Group Inc. now owns 748 shares of the medical research company’s stock worth $379,000 after buying an additional 38 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TMO. Barclays increased their price objective on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a report on Thursday, April 25th. Citigroup started coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price for the company. Evercore ISI lifted their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Finally, Raymond James boosted their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $607.35.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The disclosure for this sale can be found here. Insiders sold 62,277 shares of company stock worth $35,373,364 in the last 90 days. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $572.38 on Friday. The stock has a 50 day moving average of $575.39 and a two-hundred day moving average of $532.82. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $218.48 billion, a P/E ratio of 36.71, a P/E/G ratio of 2.37 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The company had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a $0.39 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.